Literature DB >> 23314805

Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?

Jean-Michel Pawlotsky1.   

Abstract

Hepatitis C virus (HCV) RNA level monitoring is currently used to guide the duration of interferon-containing treatment regimens. Nowadays, HCV RNA level quantification is based on real-time polymerase chain reaction assays that are both sensitive and accurate. Assessing the virological response to therapy is used to shorten treatment duration in early responders, in order to reduce the cost and burden of adverse events of therapy without impacting the chance of success. Whether response-guided therapy will still be useful in the era of all-oral, interferon-free regimens remains uncertain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23314805     DOI: 10.1007/s11894-012-0309-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  31 in total

1.  Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Syria Laperche; Christophe Hézode; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

Review 2.  New virologic tools for management of chronic hepatitis B and C.

Authors:  Stéphane Chevaliez; Christophe Rodriguez; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.

Authors:  Johannes Vermehren; Giuseppe Colucci; Peter Gohl; Nabila Hamdi; Ahmed Ihab Abdelaziz; Ursula Karey; Diana Thamke; Heike Zitzer; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

4.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

5.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Authors:  José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

6.  A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

Authors:  Marcelo Silva; Jorge Poo; Frank Wagner; Mary Jackson; David Cutler; Michael Grace; Ronald Bordens; Connie Cullen; Joann Harvey; Mark Laughlin
Journal:  J Hepatol       Date:  2006-04-18       Impact factor: 25.083

7.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors:  Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

8.  Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Authors:  Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

9.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

10.  Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Rozenn Brillet; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

View more
  3 in total

Review 1.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

Review 3.  Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.

Authors:  Guido Antonelli; Carolina Scagnolari; Federica Moschella; Enrico Proietti
Journal:  Cytokine Growth Factor Rev       Date:  2014-12-30       Impact factor: 7.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.